Effect of Lactulose on Minimal Hepatic Encephalopathy and Health-Related Quality of Life
Information source: Postgraduate Institute of Medical Education and Research
Information obtained from ClinicalTrials.gov on June 20, 2008 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Minimal Hepatic Encephalopathy; Hepatic Encephalopathy
Intervention: Lactulose (Drug)
Phase: Phase 4
Status: Completed
Sponsored by: Postgraduate Institute of Medical Education and Research Official(s) and/or principal investigator(s): Radha K Dhiman, MD,DM, FACG, Principal Investigator, Affiliation: Postgraduate Institute of Medical Education and Research, Chandigarh-160012, India
Summary
Minimal hepatic encephalopathy (MHE) has a negative effect on patients’ daily functioning. No
study has so far investigated the effect of treatment related improvement in cognitive
functions on health related quality-of-life (HRQOL). This study was carried out to determine
the influence of treatment on psychomotor performance and on HRQOL in patients with MHE.
The mean number of abnormal NP tests decreased significantly in patients in treated group
compared with patients in untreated group MANOVA for time and treatment, P =.001). Mean
total SIP score improved among patients in the treated group after 3 months compared with
patients in untreated group after 3 months (MANOVA for time and treatment, P=.002).
Improvement in HRQOL was related to the improvement in psychometry. In conclusion, treatment
with lactulose improves both cognitive functions and HRQOL in cirrhotic patients with MHE.
Clinical Details
Study design: Treatment, Randomized, Open Label, Placebo Control, Single Group Assignment, Efficacy Study
Primary outcome: Improvement in minimal hepatic encephalopathy and health related quality of life
Detailed description:
The study has been published in March 2007 in Hepatology
Lactulose Improves Cognitive Functions and Health-Related Quality of Life in Patients with
Cirrhosis WhoHave Minimal Hepatic Encephalopathy. Srinivasa Prasad, Radha K. Dhiman, Ajay
Duseja, Yogesh K. Chawla, Arpita Sharma, and Ritesh Agarwal. (HEPATOLOGY 2007;45: 549-559.)
Eligibility
Minimum age: N/A.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- All the patients diagnosed as having cirrhosis of liver
Exclusion Criteria:
- Overt HE or a history of overt HE;
- History of recent (< 6 weeks) alcohol intake;
- Infection, recent (< 6 weeks) antibiotic use or gastrointestinal bleeding;
- History of recent (< 6 weeks) use of drugs affecting psychometric
- Performances like benzodiazepens, antiepileptics, psychotropic drugs;
- History of shunt surgery or transjugular intrahepatic portosystemic shunt for portal
hypertension;
- Electrolyte imbalance;
- Renal impairment;
- Presence of hepatocellular carcinoma;
- Severe medical problems such as congestive heart failure, pulmonary disease,
neurological or psychiatric disorder, etc., that could influence quality-of-life
measurement;
- Inability to perform NP tests and to complete the SIP questionnaire due to bad
vision.
Locations and Contacts
Postgraduate Institute of Medical Education and Research, Chandigarh, UT 160012, India
Additional Information
Starting date: January 2004
Ending date: December 2004
Last updated: March 1, 2007
|